Prostamax vs Testagen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 10 mg per day
- Frequency
- Daily for 10–30 days
- Daily for 10–30 days
- Key Benefits
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Supports endogenous testosterone synthesis via Leydig cell normalization
- Promotes spermatogenesis and sperm quality
- Anti-aging effects on testicular tissue
- May attenuate age-related testosterone decline
- Mechanistically distinct from TRT — does not suppress HPG axis
- Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
- Supports male fertility without exogenous hormone replacement
- Side Effects
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Generally well tolerated
- Mild injection site reactions
- No significant endocrine disruption reported at standard doses
- Stacks With
- —
- —